What is ProSurg?
ProSurg Inc. operates at the intersection of medical engineering and clinical efficiency, focusing on the design and commercialization of proprietary products for minimally invasive prostate surgery and the treatment of abnormal uterine bleeding. The company distinguishes itself through a product portfolio that includes the NeoScope and Salinetrode Flex, both engineered for seamless integration with existing endoscopic infrastructure and radiofrequency generators. By prioritizing compatibility with standard hospital equipment, ProSurg effectively lowers the barrier to adoption for healthcare providers, positioning itself as a high-growth entity in the medical technology sector. Their market strategy centers on addressing complex urological and gynecological disorders through precision-focused, patient-centric surgical solutions.
How much funding has ProSurg raised?
ProSurg has raised a total of $106K across 1 funding round:
Debt
$106K
Debt (2021): $106K with participation from PPP
Key Investors in ProSurg
PPP
Public-Private Partnership
What's next for ProSurg?
With the infusion of this latest capital, ProSurg is well-positioned to accelerate its commercial expansion and deepen its research and development pipeline. The company is expected to focus on scaling the distribution of its proprietary surgical instruments while potentially exploring new clinical applications for its core technology. As the firm transitions through this late-stage funding phase, the strategic priority will likely shift toward capturing greater market share in the minimally invasive surgery space and establishing long-term partnerships with major healthcare systems. Continued investment in clinical validation and product iteration will be essential for maintaining its competitive edge against established medical device incumbents.
See full ProSurg company page
